MedTrace Logo

Misoprostol for the Treatment of Postpartum Hemorrhage

NCT00116350 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1786

Last updated 2009-03-19

No results posted yet for this study

Summary

The purpose of this study is to test whether misoprostol is as effective as oxytocin for treating primary postpartum hemorrhage (PPH) with uterine atony as the suspected cause in two circumstances: 1) where women have received prophylactic uterotonics in the third stage of labor; and 2) where no prophylactic uterotonics have been given in the third stage of labor.

Conditions

  • Postpartum Hemorrhage

Interventions

DRUG

Misoprostol

800 mcg sublingual misoprostol

DRUG

Oxytocin

40 IU Oxytocin IV

Sponsors & Collaborators

  • Family Care International

    collaborator OTHER

  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Beverly Winikoff, MD, MPH · Gynuity Health Projects

  • Jennifer Blum, MPH · Gynuity Health Projects

  • Rasha Dabash, MPH · Gynuity Health Projects

  • Sheila Raghavan, M.Sc. · Gynuity Health Projects

  • Ayisha Diop, MPH · Gynuity Health Projects

  • Ilana Dzuba, M.H.Sc. · Gynuity Health Projects

  • Jill Durocher · Gynuity Health Projects

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Burkina Faso
  • Ecuador
  • Egypt
  • Turkey (Türkiye)
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116350 on ClinicalTrials.gov